NCT05503797

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2023-02-21Est. Completion: 2027-12-31

Enrollment target: 254 participants

Locations

Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
University of California Los Angeles Rheumatology, Westwood, Los Angeles, California, United States
Norwalk Hospital, Norwalk, Connecticut, United States
University of Miami Hospital and Clinics, Miami, Florida, United States
The John Hopkins Hospital, Baltimore, Maryland, United States
Maryland Oncology Hematology- Columbia, Rockville, Maryland, United States
Tufts Medical Center, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
St. Luke's Hospital, Duluth, Minnesota, United States
Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph, Missouri, United States
Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha, Nebraska, United States
Overlook Medical Center, Summit, New Jersey, United States
Columbia University Irving Medical Center, New York, New York, United States

Low Grade GliomaHigh Grade Glioma

Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated …

Washington D.C., United StatesEst. completion Dec 2028

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosisBRAF Gene MutationBRAF V600EBRAF V600 MutationBRAF Mutation-Related Tumors

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.